Rua Bioscience continues Australian expansion
2
nd
April 2024
FOR PUBLIC RELEASE
Rua Bioscience conƟnues Australian expansion.
TairawhiƟ, New Zealand – Rua Bioscience is conƟnuing to expand its offering in Australia, one of the
largest medicinal cannabis markets in the world.
With company licences and distribuƟon channels established in 2023, Rua successfully launched into
this key market last September with a dried flower product.
It has now extended the range with the introducƟon of full spectrum oil products and liquid
vaporisaƟon cartridges.
“Australia has always been an important focus for us,” said CEO Paul Naske.
“Now that we have a broader range of products available in Australia, we are well posiƟoned to
develop a strong sales presence and build the Rua brand there.”
This push into Australia is supported by Rua’s recent appointment of their first Australian-based Chief
of Sales and MarkeƟng, to drive growth and market share.
“Rua’s strategy is to commercialise our unique geneƟcs on a global scale,” added Mr Naske. “In the
coming months, we’re aiming to launch a range of medicinal cannabis products using our New
Zealand geneƟcs into the Australian market.”
ENDS
The person who authorised this announcement:
Paul Naske
Chief ExecuƟve Officer
paul.naske@ruabio.com
+64 21 445154
For media inquiries, please contact:
Paul Naske - paul.naske@ruabio.com
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- AFT — AFT Pharmaceuticals Limited: AFT reports record revenue and earnings2024-05-22
“Australia NEW PRODUCT LAUNCHES FUELLING GROWTH Revenue in Australia grew 15% led by a mixture of organic and new product growth to $108.2 million from $94.1 million in the prior year. Growth came from the OTC channel which was up 24% with the company seeing good demand across…”
- AFT — AFT Pharmaceuticals Limited: NEW YEAR LETTER TO INVESTORS2024-01-08
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com It is important to temper growth expectations in these markets. As we have demon…”
- MEE — Me Today Limited: Me Today half year results and restructure plan2024-02-27
“2 Subject to approval from shareholders, the new capital is being raised at 8 cents per share. The raise will be via a partially underwritten non-renounceable rights issue, providing all shareholders the opportunity to participate in the raise should they wish to do so. Li…”